Beyond these anti‐PD‐1 agents, sugemalimab, an anti‐PD‐L1 antibody, was investigated in first‐line treatment settings in conjunction with chemotherapy vs. chemotherapy alone in metastatic NSCLC within the GEMSTONE‐302 trial [44]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.